The Prognostic Importance of Prostate-Specific Antigen in Monitoring Patients Undergoing Maximum Androgen Blockade for Metastatic Prostate Cancer

2005 ◽  
Vol 72 (3) ◽  
pp. 325-330
Author(s):  
A. Kiper ◽  
O. Yigitbasi ◽  
A. Imamoglu ◽  
C. Tuygun ◽  
C. Turan
Keyword(s):  
Prostate Cancer ◽  
Prognostic Factor ◽  
Prostate Specific Antigen ◽  
Metastatic Prostate Cancer ◽  
Specific Antigen ◽  
Time To Progression ◽  
Group 3 ◽  
Group 2 ◽  
Androgen Blockade ◽  
Group 1

The changes in serum prostate-specific antigen (PSA) concentrations can be used as a prognostic factor in patients undergoing maximum androgen blockade for metastatic prostate cancer. Materials and methods One hundred and forty-nine patients followed-up in our department were classified into four groups based on PSA changes. Group 1, those with a normalization of PSA levels within the 1st 3 months; group 2, those with a normalization of PSA levels between months 3 and 6; group 3, those with a reduction in PSA levels, but not reaching the normal range; group 4, those with no reduction in PSA levels. The gleason scores and the number of bone metastases were also compared between the groups. Results The time to progression was significantly delayed in group 1 (mean: 23.3 months) compared to that of group 2 (mean: 16.9 months) (p<0.02). The time to progression in group 3 (mean: 8.45 months) was significantly shorter compared to groups 1 and 2 (p<0.001). In addition, in patients with gleason scores 5–7 (grade 2) and gleason scores >7 (grade 3) and in group 1, the time to progression (mean: 21.2 months) was significantly delayed compared to those with the same gleason scores but in group 2 (mean: 13.4 months) (p<0.001). Conclusion The reduction in PSA levels is more important than gleason scores in determining the time to progression. Early normalization of PSA levels delays the time to progression, and when combined with gleason scores, PSA is an important prognostic factor in predicting the success of the therapy.

scholarly journals The Prognostic Importance of Prostate-Specific Antigen in Monitoring Patients Undergoing Maximum Androgen Blockage for Metastatic Prostate Cancer

2005 ◽  
Vol 5 ◽  
pp. 118-124
Author(s):  
Ahmet Kiper ◽  
Orhan Yiğitbasi ◽  
Abdurrahim Imamoglu ◽  
Can Tuygun ◽  
Celaleddin Turan
Keyword(s):  
Prostate Cancer ◽  
Prognostic Factor ◽  
Prostate Specific Antigen ◽  
Metastatic Prostate Cancer ◽  
Specific Antigen ◽  
Time To Progression ◽  
Group 4 ◽  
Prognostic Importance ◽  
Group 2 ◽  
Grade 3

The changes in serum prostate-specific antigen (PSA) concentrations can be used as a prognostic factor in patients undergoing maximum androgen blockage for metastatic prostate cancer. A total of 149 patients followed in our department were classified into 4 groups on the basis of PSA changes: group 1, those with normalisation of PSA levels within the first 3 months; group 2, those with normalisation of PSA between months 3 and 6; group 3, those with a decrease in PSA, but not reaching normal range; group 4, those with no decrease. The gleason scores and the number of bone metastases were also compared between the groups. Again time to progression in patients with Gleason scores 5-7 (grade 2) and over 7 (grade 3) whose PSA levels decreased between first and 3rd months (mean 21.2 months) were significantly longer than the patients with same gleason scores whose PSA levels decreased between 3rd and 6th months (mean 13.4 months) (p < 0.001). The decrease in PSA level is more important than gleason scores in determining the time to progression. Early normalisation of PSA delays the time to progression and when combined with gleason scores, PSA is an important prognostic factor in predicting the success of the therapy.

The prognostic value of mid-treatment prostate-specific antigen level in patients receiving salvage radiotherapy.

2019 ◽  
Vol 37 (7_suppl) ◽  
pp. 289-289
Author(s):  
Jason Homza ◽  
John T. Nawrocki ◽  
Harmar D. Brereton ◽  
Christopher A. Peters
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Salvage Radiotherapy ◽  
Clinical Failure ◽  
Treatment Intensification ◽  
Significant Difference ◽  
Group 2 ◽  
Group 1

289 Background: Salvage radiotherapy (SRT) may be employed as a potentially curative intervention for patients experiencing biochemical failure (serum prostate-specific antigen [PSA] ≥ 0.2 ng/mL) after prostatectomy for localized prostate cancer. Patients not showing a favorable response to SRT alone may require additional therapies and may benefit from earlier identification of this need. Methods: 131 consecutive patients received SRT during the timeframe of this study. 76 were deemed eligible based on the following criteria: prostatic adenocarcinoma diagnosis receiving SRT, no clinical evidence of metastasis, no hormone use prior to/during SRT, serum PSA measurement halfway through SRT, and minimum follow-up time of 3 months. Median follow-up time was 51.6 months. Eligible patients were divided into three groups based on PSA response by the midpoint of treatment: no change, decrease, or increase in PSA. The primary endpoint of the study was clinical failure (measured from SRT completion), defined as serum PSA value ≥0.2ng/mL above the post-radiotherapy nadir, initiation of androgen deprivation therapy, development of bone metastasis, or death from prostate cancer. Results: 13.1% experienced no change in PSA halfway through SRT (group 0), 68.4% of patients experienced a decrease (group 1), 18.4% experienced an increase (group 2). Four-year freedom from clinical failure was 60.0% for group 0, 58.3% for group 1, and 41.7% for group 2. Median time to clinical failure was 71.7 months for group 1, 26.8 months for group 2, and was not reached for group 0. Pairwise multiple comparison demonstrated a significant difference in four-year freedom from clinical failure between groups 1 and 2 (p = 0.036). Conclusions: These data strongly suggest that changes in PSA are apparent midway through SRT and are associated with 4-year freedom from clinical failure. Further study is warranted to determine whether mid-treatment PSA during SRT may be used to identify a subset of patients that may benefit from treatment intensification.

scholarly journals The importance of PSA-Density in active surveillance for prostate cancer

2020 ◽  
Vol 92 (2) ◽  
Author(s):  
Caner Ediz ◽  
Serkan Akan ◽  
Muhammed Cihan Temel ◽  
Omer Yilmaz
Keyword(s):  
Prostate Cancer ◽  
Treatment Group ◽  
Prostate Specific Antigen ◽  
Active Surveillance ◽  
Specific Antigen ◽  
Tumor Burden ◽  
Additional Treatment ◽  
Group 2 ◽  
Group 1

Objective: In this study, we aimed to determine the predictive factor for additional treatment requirement in active surveillance (AS) for patients with low or very low-risk prostate cancer (PCa) and we investigated the effect of tumor burden by total core involvement rate in biopsy to predict of need for additional treatment.Material and methods: 107 patients with PCa in AS between 2005 and 2018 have been evaluated retrospectively. Groups were divided into two groups according to the need for additional treatment. Group 1 received additional treatment, group 2 did not receive additional treatments and active surveillance was continued. Patient’s total prostate-specific antigen (tPSA), prostate-specific antigen density (PSA-D), total core involvement count, quantity and rate at biopsy pathology results and follow-up period were recorded and compared in the two groups. Results: The current cohort includes 107 patients. Mean age at diagnosis was 63.01years. Mean tPSA values at diagnosis were 6.09 ng/mL and 5.2 ng/mL in the group 1 and group 2, respectively. Mean follow-up period was 38.1 months (range, 12 to 134 months). Only PSA-D measurement significantly predicted need for additional treatment (p = 0.017). ROC analysis showed that the optimal threshold was 0.13 ng/mL/cc (sensitivity: 70.8%; specificity: 57.1%). Additional treatment requirement was not detected in patients with PSA-D cut-off level less than 0.07 ng/mL/cc. Conclusions: Total tumor burden of less than 5% is safe for patients with low or very low-risk PCa in AS. A 0.13 ng/mL/cc cut-off level of PSA-D can predict to need for additional treatment in patients managed by AS.

scholarly journals The effects of cigarette smoking on prostate-specific antigen in two different age groups

2013 ◽  
Vol 7 (11-12) ◽  
pp. 704 ◽  
Author(s):  
Gokhan Koc ◽  
Korhan Akgul ◽  
Yuksel Yilmaz ◽  
Alper Dirik
Keyword(s):  
Cigarette Smoking ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Age Groups ◽  
Group 4 ◽  
Significant Difference ◽  
Group 3 ◽  
Group 2 ◽  
Age Range ◽  
Group 1

Background: We investigate the effects of cigarette smoking on prostate-specific antigen (PSA) using 2 different age groups.Methods: The study was carried out between January 2007 and October 2011 with men; the 2 sets of age groups were: 25 to 35 years and 50 to 70 years old. The participants were divided into 4 groups. Of the 25 to 35 age range, smokers were Group 1, and non-smokers were Group 2; of the 50 to 70 age range, smokers were Group 3 and non-smokers Group 4. In addition, for the 50 to 70 age group, the International Prostate Symptom Score was completed, digital rectal examination was performed, and transabdominal prostate volume was measured. We wanted to see whether prostate-specific antigen (PSA) levels showed a difference between the 2 age groups.Results: There were 114 patients in Group 1, 82 in Group 2,90 in Group 3, and 102 in Group 4. The mean PSA level was 0.7 ± 0.28 ng/mL for Group 1, and 0.6 ± 0.27 ng/mL for Group 2 (p = 0.27), and there was no statistically significant difference between the 2 groups. The mean PSA was 2.5 ± 1.8 ng/mL for Group 3, and 2.1 ± 2.0 ng/mL (p = 0.59) for Group 4, and there was no statistically significant difference between the these 2 age groups.Interpretation: Cigarette smoking effects various hormone levels. Different from previous studies, the PSA level was higher in smokers compared to nonsmokers, although it was not statistically significant. Our study is limited by the small numbers in our study groups and the lack of PSA velocity data.

Sign in / Sign up

Export Citation Format

Share Document